论文部分内容阅读
目的观察心律失常患者采用普罗帕酮与胺碘酮治疗的临床疗效及血清hs-CRP的变化情况。方法拟选取2014至2015年入住我院的86例心律失常患者作为研究对象,依据临床治疗方法不同将所选病例分为采用普罗帕酮治疗的对照组与使用胺碘酮治疗的观察组,将两组治疗效果与治疗前后血清hs-CRP变化情况作以比较。结果观察组治疗获得有效共计41例(95.4%)多于对照组35例(81.4%),组间差异有统计学意义(P<0.05);治疗后观察组血清hs-CRP水平为(7.8±1.9)mg/l低于对照组(18.6±4.7)mg/l,两组差异突出有统计学意义(P<0.05)。结论在心律失常治疗中胺碘酮治疗方案临床效果优于普罗帕酮方案,能很好控制患者血清中hs-CRP水平,临床应用效果良好。
Objective To observe the clinical efficacy of propafenone and amiodarone in patients with arrhythmia and the changes of serum hs-CRP. Methods Totally 86 cases of arrhythmia admitted to our hospital from 2014 to 2015 were selected as the research object. According to the different clinical treatment methods, the selected cases were divided into the control group treated with propafenone and the observation group treated with amiodarone. The two groups of treatment and serum hs-CRP changes before and after treatment for comparison. Results There were 41 cases (95.4%) in observation group and 35 cases (81.4%) in control group, the difference was statistically significant (P <0.05). After treatment, the serum hs-CRP level in observation group was 7.8 ± 1.9) mg / l was lower than that of the control group (18.6 ± 4.7) mg / l, with significant differences between the two groups (P <0.05). Conclusions The clinical effect of amiodarone treatment in arrhythmia treatment is better than that of propafenone regimen, which can well control the serum hs-CRP level in patients with arrhythmia. The clinical effect is good.